| genetic
disease, genetic engineering, custom chip design, genotyping
services, human high-throughput genotyping, microarray design,
genome, Apex, development, arrayed primer extension, SNP,
genomics, genetic testing services, SNP tests, DNA chip, arrayed primer
extension, microarray scanner, p53, drug development,
diagnostics, personalized treatment,
human medicine, SNP, biotechnology, technology transfer, gene, DNA test |
04.2008 |
The Ashkenazi Jewish diseases
test updated
The
chip has been updated by adding 8 new mutations to the
test. The current test version covers 77 mutations from 22
different genes related to Cystic Fibrosis, Tay Sachs, Bloom -,
Canavan -, Niemann-Pick A syndrome, Familian dysautonomia,
Torsion dystonia, Mucolipidosis IV, Fanconi Anemia, Factor XI
deficiency, Glycogen storage disease, Marple Syrup Urine
disease, Nonsyndromic sensorineural hearing loss, Familial
mediterranean fever, Alpha
1-anti-trypsin Deficiency, Nemaline Myopathy, Usher Syndrome
Type 1F, Familial hyperinsulinemia, Familial
Hypercholesterolemia,
Gaucher disease and Lipoamide Dehydrogenase Deficiency,
Gaucher disease and Lipoamide Dehydrogenase Deficiency.
|
|
|
04.2008 |
New
publication co-authored by Asper scientist was published:
Genotyping microarray as a novel approach for the detection of
ATP7B gene mutations in patients with Wilson disease
Gojova L., Jansova E., Külm M., Pouchla S., Kozak L.
Clinical Genetics 2008: 73: 441–452
|
|
|
04.2008 |
Asper Ophthalmics will be
represented at the 15th Retina International World Congress
"Research into practice" with its exhibition stand.
The
congress will be held in Finlandia Hall, Helsinki, Finland on 4th-5th
July, 2008. Asper welcomes all existing partners and everyone interested in
collaboration with Asper to attend the congress and meet in its booth.
|
|
|
03.2008 |
Leber
congenital amaurosis chip updated
44
new mutations and 1 new gene (LCA5) can be analyzed by LCA
chip. Currently
the test can be used for the screening of 495 mutations in 12
genes: AIPL1,
CRB1, CRX, GUCY2D, LRAT, MERTK, CEP290, RDH12, RPGRIP1, RPE65,
LCA5 and TULP1.
|
|
|
02.2008 |
Corneal
dystrophy
assay updated
Corneal
dystrophy chip
has been updated by adding 68 new mutations to the test. The
current test version covers 297 different mutations from 12
genes:
COL8A2, TGFBI, VSX1, CHST6, KRT3, KRT12, GSN, TACSTD2,
CYP4V2, SOD1, TCF8/ZEB1, SLC4A11.
|
|
|
02.2008 |
Asper Ophthalmics will be represented at the ARVO
2008 - Eyes on Innovation - in Fort Lauderdale,
Florida, USA, on April 27-April 30.
As
last three years, Asper will be represented at the meeting of the Association for
Research in Vision and Ophthalmology (ARVO) 2008. The meeting will be held
in Broward County Convention Center, Fort
Lauderdale, Florida, USA on April 27 - April 30.
Asper welcomes all existing partners and everyone interested in
collaboration with Asper to attend the conference and meet in its booth
#715.
|
|
|
02.2008 |
Asper
Biotech invites all interested to its booth #444 at the 40th
European Human Genetics Conference - ESHG 2008 in Barcelona, Spain, 31
May - 3 June.
Asper will be represented at the 40th
European Human Genetics Conference - ESHG 2008. The
conference will be held in Center Convencions Internacional Barcelona -
CCIB, Barcelona, Spain on May 31-June 3.
Asper welcomes all existing partners and everyone interested in
collaboration with Asper to attend the conference and meet in its
booth #444.
|
|
|
11.2007 |
The
Estonian Biocentre (EBC) and Asper Biotech Ltd signed a
licencing agreement that authorises Asper Biotech to use
„Analysis Method of Risk Alleles for estimation of
predisposition
of Inheritant Breast and Ovarian Cancer“ which
has been recognised as a utility model.
The
utility model describes recently discovered risk alleles in the
Estonian population as well as their analysis, together with the
risk alleles of breast and ovarian cancer, which have already
been described in public databases.
Asper Biotech Ltd is a spin-off company of the Estonian
Biocentre and Tartu University, established in 1999 and
specialised in genetic test development and offering the service
of DNA analysis. The establishment’s services are available in
over 30 countries, being the biggest exporter in the Estonian
sector of biotechnology.
The Estonian Biocentre (EBC) was established in 1986 by the
decree of the government as a state owned scientific and
educational institution. The main research direction of the EBC
lies in the field of molecular medicine and is linked to
biotechnology.
|
|
|
|
 
|
Genorama®
SAL
Genorama®
SA
|
